Jefferies Group LLC reaffirmed their buy rating on shares of Incyte Corporation (NASDAQ:INCY) in a research note issued to investors on Thursday. They currently have a $148.00 price objective on the biopharmaceutical company’s stock.

INCY has been the subject of a number of other reports. Oppenheimer Holdings, Inc. set a $125.00 price target on Incyte Corporation and gave the company a hold rating in a research note on Thursday, May 18th. BMO Capital Markets increased their price target on Incyte Corporation from $144.00 to $146.00 and gave the company an outperform rating in a research note on Friday, May 5th. TheStreet cut Incyte Corporation from a b- rating to a c+ rating in a research note on Monday, April 17th. Credit Suisse Group set a $167.00 price target on Incyte Corporation and gave the company a buy rating in a research note on Wednesday, April 19th. Finally, J P Morgan Chase & Co set a $149.00 price target on Incyte Corporation and gave the company a buy rating in a research note on Thursday, May 18th. Seven analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Incyte Corporation has a consensus rating of Buy and a consensus price target of $141.30.

Shares of Incyte Corporation (NASDAQ INCY) traded down 1.80% during trading on Thursday, reaching $133.29. The company’s stock had a trading volume of 1,207,848 shares. The stock’s market capitalization is $27.29 billion. The firm’s 50-day moving average is $129.47 and its 200-day moving average is $128.67. Incyte Corporation has a 12-month low of $75.52 and a 12-month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. The company had revenue of $384.08 million during the quarter, compared to analysts’ expectations of $359.19 million. During the same period last year, the business posted $0.12 earnings per share. The firm’s revenue was up 45.8% compared to the same quarter last year. Equities analysts expect that Incyte Corporation will post ($0.74) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/jefferies-group-llc-reaffirms-buy-rating-for-incyte-corporation-nasdaqincy/1464594.html.

In other news, Director Jean Jacques Bienaime purchased 500 shares of the stock in a transaction dated Monday, May 15th. The shares were purchased at an average cost of $115.00 per share, with a total value of $57,500.00. Following the completion of the purchase, the director now directly owns 4,177 shares of the company’s stock, valued at approximately $480,355. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO David W. Gryska sold 16,756 shares of Incyte Corporation stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $116.60, for a total value of $1,953,749.60. Following the completion of the sale, the chief financial officer now directly owns 35,771 shares in the company, valued at $4,170,898.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,940 shares of company stock worth $6,381,746. 17.70% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of INCY. State Street Corp raised its stake in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock worth $1,013,437,000 after buying an additional 3,983,207 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after buying an additional 2,847,907 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Incyte Corporation during the first quarter worth about $85,751,000. Geode Capital Management LLC raised its stake in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after buying an additional 526,163 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Incyte Corporation by 117.6% in the first quarter. Morgan Stanley now owns 776,654 shares of the biopharmaceutical company’s stock worth $103,815,000 after buying an additional 419,732 shares in the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.